scholarly journals Icteric Index

2020 ◽  
Author(s):  
Keyword(s):  
2021 ◽  
Vol 31 (2) ◽  
Author(s):  
Rufino Mondejar ◽  
María Mayor Reyes ◽  
Enrique Melguizo Madrid ◽  
Consuelo Cañavate Solano ◽  
Santiago Pérez Ramos

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S31-S31
Author(s):  
R Alqabbani ◽  
D Stickle

Abstract Introduction/Objective Our cardiac intensive care unit (CICU) asked the laboratory to provide plasma hemoglobin testing to monitor effects of ventricular-assist devices (VAD). Roche hemolysis index (HI) has been reported to be suitable for this purpose. Use of HI as a reportable test, however, must be validated in-house as a laboratory- developed test (LDT), according to CLIA regulations. We describe results of our evaluation, and caveats for intended use. Methods/Case Report Concentrated hemolysate was produced by osmotic lysis of packed red blood cells in water. Hemolysis in plasma was by dilution of concentrated hemolysate. Verification of HI as a measure of hemoglobin (mg/dL) used the Sigma-Aldrich spectrophotometric hemoglobin assay as a gold standard. Linearity, linear range, sensitivity, were investigated by dilution measurements; interferences by admixture experiments; reproducibility (precision, intra- and inter-assay) in each case by replicate measurements (n = 20). Results (if a Case Study enter NA) HI was confirmed to correspond to hemoglobin in mg/dL. Linearity was between 2-1000 mg/dL (r2 >0.99). Intra-assay precisions were <=2.5% (hemoglobin = 74,148 mg/dL); inter-assay precisions were <=4.9% (hemoglobin = 69,139 mg/dL). HI variability was ±2 at very low values (0-10 mg/dL). There were no interferences observed among common therapeutic drugs. Hyperlipemia (evaluated up to lipemic index (LI) = 225) and hyperbilirubinemia (evaluated up to icteric index (II) = 7) demonstrated no significant interference. Conclusion Analytically, HI exhibited acceptable performance for reporting of plasma hemoglobin. Deployment would require establishment of quality control (QC) and proficiency testing procedures for HI. Clinically, a caveat for use is that HI cannot distinguish between hemolysis in circulation vs. that due to sample collection. For the CICU, HI >10 mg/dL is characteristic of more than 20% of samples drawn in general, irrespective of use of VAD. Temporal patterns of HI must therefore be carefully evaluated in parallel with haptoglobin measurements to assist in VAD management.


2019 ◽  
Vol 493 ◽  
pp. S7
Author(s):  
A. Arbiol-Roca ◽  
M.R. Navarro-Badal ◽  
E. Mariano-Serrano ◽  
A. Ferri-Font ◽  
N. Aisa-Abdellaoui ◽  
...  
Keyword(s):  

1978 ◽  
Vol 27 (2) ◽  
pp. 237-240 ◽  
Author(s):  
O. P. Nangia ◽  
R. D. Rana ◽  
Narinder Singh ◽  
A. Ahmad

ABSTRACTCastrated and entire male buffalo calves of about 2 years of age were made to work by pulling a stone roller weighing 80 kg at a constant speed of about 3 km/h on even ‘Kachha’ ground for 3 h. Blood levels of lactic acid and pyruvic acid and the Icteric index increased, whereas blood levels of bicarbonate and proteins decreased in response to exercise. No change was observed in blood glucose or chloride levels. There was no difference in the concentrations of blood constituents of the two groups.


2020 ◽  
Vol 13 (6) ◽  
pp. e234702
Author(s):  
Joel James ◽  
Madelena Stauss ◽  
Arvind Ponnusamy ◽  
Martin Myers

​Serum concentrations of paracetamol are measured to investigate the cause of acute hepatitis, monitor the clearance of paracetamol from the body and to determine if supratherapeutic levels warrant treatment with N-acetylcysteine (NAC). ​A 49-year-old man treated for ischaemic colitis developed worsening renal and liver function tests. As part of the investigation of hepatorenal failure, paracetamol levels were requested, which were elevated at 14 mg/L (normal <4 mg/L) resulting in treatment with NAC. Despite treatment, levels of paracetamol remained elevated and the link between hyperbilirubinemia and false-positive paracetamol levels was identified. ​Bilirubin and its by-products have intense absorbance in the ultraviolet and visible regions of the electromagnetic spectrum, causing interference in the enzymatic colorimetric assay most commonly used to measure paracetamol concentration, resulting in false-positive paracetamol levels. Laboratories correct for this interference above a predetermined bilirubin concentration, termed the Icteric Index; however, in our case this interference occurred at a lower level of hyperbilirubinaemia than previously identified as significant. This interaction was found to be more significant at lower bilirubin levels when low or no paracetamol levels were present in the serum, resulting in a change to laboratory practice and development of a ‘Sliding Scale’ approach to analysis. ​Concurrent bilirubin or Icteric Index measurement is recommended for all laboratories that use the enzymatic colorimetric assay for paracetamol measurement. Lower Icteric Index or bilirubin thresholds are required when low or no paracetamol levels are present in the serum to prevent false-positive paracetamol results. We describe a new ‘Sliding Scale’ approach to analysis, and highlight an important interaction for clinicians to be aware of.


2012 ◽  
Vol 65 (10) ◽  
pp. 928-933 ◽  
Author(s):  
Maria Salinas ◽  
Maite López-Garrigós ◽  
Javier Lugo ◽  
Mercedes Gutiérrez ◽  
Lucia Flors ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document